Whole-body diffusion-weighted MRI and fluorine 18–fluorodeoxyglucose PET/CT, with response criteria applied to each imaging technique, are becoming increasingly important in the posttreatment assessment of multiple myeloma.
Jiménez-Vázquez et al. (Thu,) studied this question.